Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07308392 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Final enrollment: 119 participants (planned 108) · Site details revisedv4 Show 2 more changesShow less
    • Final enrollment: 119 participants (planned 108)
    • Site details revised
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2025 to Feb 25, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2025 to Feb 25, 2026
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis
Trial Details
NCT Number NCT07308392
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Enrollment 119 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov